ADAR1 Capital Management »

Relmada Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Relmada Therapeutics (RLMD) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Relmada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Relmada Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Relmada Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $152k 51k 3.00
2024-03-31 $2.8k 601 4.65
2023-12-31 $243k 59k 4.14

More positions owned by ADAR1 Capital Management

Cytokinetics Com New (CYTK)
Protagonist Therapeutics (PTGX)
Bridgebio Pharma (BBIO)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Ascendis Pharma A/s Sponsored Adr (ASND)
Zura Bio Class A Ord Shs (ZURA)
Zai Lab Adr (ZLAB)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Aa Mission Acquisition Corp Ord Shs Cl A (AAM)
Mineralys Therapeutics (MLYS)
Syndax Pharmaceuticals (SNDX)

View all positions for ADAR1 Capital Management

Top funds holding Relmada Therapeutics

Franklin Resources
Vanguard Group
Acadian Asset Management
Palo Alto Investors
Deep Track Capital
Millennium Management
BlackRock
Vestal Point Capital
Opaleye Management
Jpmorgan Chase & Co
Geode Capital Management
Two Sigma Advisers
Deutsche Bank Aktiengesellschaft
Bank of America Corporation
Two Sigma Investments

View all funds holding Relmada Therapeutics